Producer
Gerresheimer AG
German pharma packaging specialist; ~30–35% global pharma glass packaging alongside Schott; acquired Bormioli Pharma Dec 2024; also produces LDPE ophthalmic dropper bottles (System A).
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Gerresheimer AG supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Gerresheimer AG makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Primary Packaging Glass (Vials, Ampoules, Cartridges)
40%Primary Packaging Plastics (Dropper Bottles + COP/COP)
30%Advanced Technologies (Drug Delivery Devices)
30%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Gerresheimer makes both the primary packaging container (glass vial, cartridge, prefilled syringe) that holds the drug AND the delivery device (auto-injector, pen needle, inhaler component) that administers the drug — a dual-layer pharmaceutical supply chain position: (1) Glass cartridges for GLP-1 drug auto-injectors: the insulin-pen format glass cartridges used for Ozempic (semaglutide) and Mounjaro (tirzepatide) pens are made by companies including Gerresheimer; the GLP-1 drug demand surge 2022-2024 created glass cartridge supply constraints as a bottleneck in the fastest-growing pharmaceutical market; (2) LDPE dropper bottles for eye drops: essentially all eye drop bottles for glaucoma, dry eye, and antibiotic ophthalmic drugs use LDPE plastic containers; Gerresheimer makes these alongside glass; (3) Inhaler devices: Gerresheimer makes DPI and MDI device components used in asthma and COPD inhaler products. The same German company is structurally embedded in: the GLP-1 obesity/diabetes drug revolution (cartridges and devices), ophthalmic disease treatment (dropper bottles), and respiratory medicine delivery (inhaler devices) — three of the most commercially significant pharmaceutical growth markets of the 2020s.
Gerresheimer AG ↗Origin2023
Gerresheimer AG traces its origins to 1864 in Gerresheim, a village then outside Düsseldorf (now incorporated into Düsseldorf), Germany — one of many glass manufacturing companies that emerged in the Rhine-Ruhr industrial region during the German industrialization era. The company specialized in specialty glass (laboratory, pharmaceutical, perfumery) rather than commodity flat glass. The pharmaceutical packaging specialization intensified through the 20th century as injectable drug manufacturing required high-quality, low-extractable borosilicate glass containers. In December 2024, Gerresheimer acquired Bormioli Pharma — an Italian company whose origins trace to the Bormioli glass family operating since 1825 in Parma — adding Italian glass manufacturing expertise and capacity to the German operation. The acquisition combined a 160-year German glass tradition with a 200-year Italian glass tradition in the pharmaceutical packaging sector — two of Europe's oldest glass companies merging to serve the same pharmaceutical market.
Gerresheimer AG ↗